AX-2026-041451

Humanin (HNG) · 10 mg declared · ChinaPeptides Co., Ltd. (QYAOBIO) · lot QYB-2512-A4980

PASSPURITY ONLY

Report ID: AX-2026-041451
Compound: Humanin (HNG)
Compound class: Metabolic and mitochondrial peptides
Supplier: QYB — ChinaPeptides Co., Ltd. (QYAOBIO)
Batch / lot: QYB-2512-A4980
Declared label claim: 10mg
Laboratory: Janoshik Analytical
Assay date: 29 Jan 2026
Submitted: 07 Feb 2026
Quarter: 2026-Q1
Submitter: vial_headspace
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the metabolic and mitochondrial peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.30	% area	≥ 97.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.70	% area	≤ 2.5	PASS
Largest single impurity	RP-HPLC — wild-type humanin (Ser14, −42 Da)	0.33	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	4.59	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.67	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.62	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear after 90 s gentle swirling, no particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.32	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	12.14	min	12.14 ± 0.30 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.06	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	50,878	—	≥ 20,000	PASS
Resolution to nearest impurity	vs wild-type humanin (Ser14, −42 Da)	0.68	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 50,878, and skew follows the reported asymmetry factor of 1.06. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.33 % impurity against a 99.30 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Humanin (HNG) — main peak	12.14	4,826,288	99.30	—
2	wild-type humanin (Ser14, −42 Da)	11.99	16,039	0.33	-42.011
3	truncated (1-20)	10.79	7,290	0.15	-472.245
4	Met sulfoxide (+16 Da)	11.72	6,318	0.13	+15.995
5	deamidated (+1 Da)	11.86	4,374	0.09	+0.984
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.67	99.30	divergence -0.60 pp vs batch median
Total impurities (% area)	1.33	0.70
Largest single impurity (% area)	not stated	0.33
Water (%)	4.1	4.59
Counter-ion (%)	not stated	5.67
Peptide content (%w/w)	not stated	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Domestic warehouse despatch → submitter (2–8 °C, 19 d) → laboratory (courier, cold pack, 7 d) → assay.
Assay date: 29 Jan 2026
Submitted to the index: 07 Feb 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

plate_count07 Feb 2026

Plate count on this run supports the separation claimed. A high purity figure from an inefficient column is a merged peak reported as a clean one; that is not what happened here.

aib_coupling07 Feb 2026

Hindered couplings are where a synthesis loses purity, and the deletion products they leave are the first thing to look for. On this record they are not there in quantity.

retest_date07 Feb 2026

A retest date on the certificate would tell you what the supplier is actually asserting about stability. Purity at 99.30 % on assay day is a starting condition, not a shelf life.

Section 7

Related records

Same batch — lot QYB-2512-A4980 n=9

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041449	QYB-2512-A4980	Janoshik	2026-Q1	99.13	4.40	—	Buyer-sourced	0	PASS
AX-2026-041450	QYB-2512-A4980	Janoshik	2026-Q1	99.12	4.88	—	Buyer-sourced	0	PASS
AX-2026-041452	QYB-2512-A4980	PeptideMeter	2026-Q1	99.01	4.14	92.6	Buyer-sourced	0	PASS
AX-2026-041453	QYB-2512-A4980	Nordanalyt	2026-Q1	99.41	4.07	89.1	Buyer-sourced	1	MARGINAL
AX-2026-041454	QYB-2512-A4980	Janoshik	2026-Q1	99.32	4.37	—	Buyer-sourced	0	PASS
AX-2026-041455	QYB-2512-A4980	Janoshik	2026-Q1	99.17	4.41	97.3	Buyer-sourced	0	PASS
AX-2026-041456	QYB-2512-A4980	Janoshik	2026-Q1	99.60	4.01	98.3	Buyer-sourced	0	PASS
AX-2026-041457	QYB-2512-A4980	Janoshik	2026-Q1	99.27	4.53	103.1	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Humanin (HNG) records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042265	TFC	TFC-2605-U1300	PeptideMeter	2026-Q3	99.52	6.31	—	Buyer-sourced	0	PASS
AX-2026-042236	TFC	TFC-2608-S9940	Nordanalyt	2026-Q3	98.64	1.80	—	Buyer-sourced	0	PASS
AX-2026-042264	TFC	TFC-2605-U1300	Nordanalyt	2026-Q3	99.62	6.67	89.5	Buyer-sourced	1	MARGINAL
AX-2026-042237	TFC	TFC-2608-S9940	Janoshik	2026-Q3	98.71	1.73	93.6	Buyer-sourced	0	PASS
AX-2026-042266	TFC	TFC-2605-U1300	Janoshik	2026-Q3	99.38	6.55	—	Laboratory-retained	1	MARGINAL
AX-2026-042235	TFC	TFC-2608-S9940	Kestrel	2026-Q3	98.59	2.01	102.2	Buyer-sourced	0	PASS
AX-2026-042240	TFC	TFC-2608-S9940	Janoshik	2026-Q3	98.50	1.95	—	Buyer-sourced	0	PASS
AX-2026-042239	TFC	TFC-2608-S9940	Janoshik	2026-Q3	98.38	2.57	96.0	Buyer-sourced	0	PASS

Other recent QYB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041471	PT-141 (Bremelanotide)	QYB-2607-L4875	Janoshik	2026-Q3	99.72	3.75	101.7	Buyer-sourced	0	PASS
AX-2026-041377	Ipamorelin	QYB-2605-H3558	Nordanalyt	2026-Q3	99.93	4.35	—	Buyer-sourced	0	PASS
AX-2026-041427	Retatrutide	QYB-2604-B4920	PeptideMeter	2026-Q3	97.93	2.45	101.7	Buyer-sourced	0	PASS
AX-2026-041428	Retatrutide	QYB-2604-B4920	Janoshik	2026-Q3	98.35	3.20	—	Laboratory-retained	0	PASS
AX-2026-041473	PT-141 (Bremelanotide)	QYB-2607-L4875	PeptideMeter	2026-Q3	99.58	3.74	94.4	Buyer-sourced	0	PASS
AX-2026-041472	PT-141 (Bremelanotide)	QYB-2607-L4875	PeptideMeter	2026-Q3	99.93	3.94	—	Buyer-sourced	0	PASS
AX-2026-041429	Retatrutide	QYB-2604-B4920	Medutest	2026-Q3	98.53	2.69	99.8	Buyer-sourced	1	MARGINAL
AX-2026-041431	Retatrutide	QYB-2604-B4920	Janoshik	2026-Q3	98.63	2.32	94.2	Buyer-sourced	0	PASS